Volition presents breakthrough liquid biopsy blood test method for early-stage cancer

Henderson, nev. , oct. 23, 2023 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, has unveiled what it believes to be an entirely new cancer detection method at esmo 2023¹, the annual congress of the european society for medical oncology.

VNRX Ratings Summary

VNRX Quant Ranking